When a GP flags a slightly elevated fasting glucose or a waist measurement that has crept up, the conversation almost always turns to the heart. Cholesterol, blood pressure, diabetes risk, maybe a follow-up test in six months. What rarely comes up in that ten minute appointment is the brain.

That is beginning to change. Over the past decade, researchers have been mapping the overlap between how the body manages energy and how the nervous system ages, and the connections are proving harder to dismiss than they once were. None of it means a borderline blood test predicts a neurological condition. It does mean the two systems are less separate than the structure of most health check-ups suggests.

For anyone already living with a neurological diagnosis, this overlap has a practical edge. Metabolic markers are among the few variables in the picture that respond to everyday choices, and they are not always picked up by standard neurological follow-up. That gap is why parkinsons metabolic screening has started coming up more often in conversations between patients and their wider care team, sitting alongside the usual monitoring rather than replacing any part of it.

The brain is an expensive organ

The brain accounts for roughly two per cent of body weight and consumes about twenty per cent of the body's energy at rest. It runs almost entirely on glucose, and it has insulin receptors distributed throughout, including in regions involved in memory and movement.

For a long time the brain was considered insulin independent. It is now understood to be anything but. Insulin signalling in the brain influences how neurons take up fuel, how they communicate and how well they clear cellular waste. When that signalling becomes blunted, as it does in insulin resistance, the effects are not confined to the pancreas and the liver. 

What the research actually shows

Two lines of evidence are worth knowing about.

The first concerns diabetes and Parkinson's disease. A meta-analysis pooling fifteen cohort studies and close to thirty million participants found that people with diabetes had a higher risk of developing Parkinson's disease than people without, with a summary relative risk of 1.27, and that prediabetes carried a smaller but still measurable association. A separate analysis combining observational data with genetic methods reached a similar conclusion, and found cohort studies provided strong evidence of the association.

The second concerns metabolic syndrome and cognition. Drawing on twenty five years of follow-up in a large British cohort, researchers found metabolic syndrome was associated with increased dementia risk overall, that the association was clearest in people in their sixties, and that a longer duration of metabolic syndrome carried greater risk. A Korean study of nearly two million adults linked metabolic syndrome in midlife to a 24 per cent higher risk of dementia before the age of 65.

These are population-level associations, not individual predictions. But they are consistent across very different populations, which is what gives them weight.

Insulin resistance can exist without a diabetes diagnosis

The more surprising finding sits underneath all of this. Insulin resistance can be well established while routine blood sugar readings still look fine.

One study tested people with Parkinson's who had no diabetes diagnosis and found that close to two thirds were insulin resistant despite normal blood sugar, suggesting the problem is common and largely undetected in this group. Insulin resistance typically produces no symptoms, which is a large part of why it goes unnoticed, and it is not confined to people carrying extra weight.

Standard testing is part of the reason. A fasting glucose reading or an HbA1c shows what blood sugar is doing, not how hard the body is working to keep it there. Someone can maintain normal readings for years by producing steadily more insulin, and nothing in a routine panel will flag it. 

What this evidence does not say

It is worth being clear about the limits, because this is an area where claims outrun the science quickly.

Association is not causation. Most of this research shows that metabolic problems and neurological conditions travel together, not that one produces the other. Some of the overlap may run in the opposite direction, since reduced mobility and altered appetite are themselves features of neurological illness.

Nor has the treatment side delivered. Diabetes medications have been trialled in Parkinson's disease on the strength of this biology, and results across studies have been mixed. No metabolic treatment is currently an approved therapy for Parkinson's disease, and nothing described here is an alternative to prescribed neurological treatment.

The levers that are within reach

What makes metabolic health worth attention is not that it offers a cure. It is that it is modifiable, which distinguishes it from age, genetics and most other factors in the picture.

The interventions are unglamorous and well established. Regular resistance training and walking improve insulin sensitivity independently of weight change. Sleep matters more than most people expect, since even short periods of poor sleep measurably reduce insulin sensitivity. Reducing ultra-processed food and added sugar helps. So does moderating alcohol.

For people with a neurological diagnosis, exercise carries a second benefit, with reasonable evidence supporting its role in maintaining mobility and function. The metabolic gain comes alongside that rather than instead of it. 

Worth raising at your next check-up

If any of this is relevant to you, a few questions are reasonable to ask a GP.

Ask whether a fasting insulin test or HOMA-IR calculation would add anything to your standard panel, particularly if there is a family history of type 2 diabetes or neurological illness. Ask what your waist circumference and triglyceride to HDL ratio suggest. Ask whether your current readings have shifted over the past five years, since the trend often says more than any single result.

None of this replaces neurological care, and anyone with an existing diagnosis should keep changes to diet or exercise within the loop of their treating team. But metabolic health has spent a long time filed under cardiovascular risk alone, and the evidence increasingly suggests that filing is too narrow.